Abstract:Introduction: Today, rapid technical and clinical developments result in an increasing number of treatment options for oncological diseases. Thus, decision support systems are needed to offer the right treatment to the right patient. Imaging biomarkers hold great promise in patient-individual treatment guidance. Routinely performed for diagnosis and staging, imaging datasets are expected to hold more information than used in the clinical practice. Radiomics describes the extraction of a large number of meaningful quantitative features from medical images, such as computed tomography (CT) and positron emission tomography (PET). Due to the non-invasive nature and ability to capture 3D image-based heterogeneity, radiomic features are potential surrogate markers of the cancer phenotype. Several radiomic studies are published per day, owing to encouraging results of many radiomics-based patient outcome models. Despite this comparably large number of studies, radiomics is mainly studied in proof of principle concept. Hence, a translation of radiomics from a hot topic research field into an essential clinical decision-making tool is lacking, but of high clinical interest. Evidence acquisition: Herein, we present a literature review addressing the clinical evidence of CT and PET radiomics. An extensive literature review was conducted in PubMed, including papers on robustness and clinical applications. Evidence synthesis: We summarize image-modality related influences on the robustness of radiomic features and provide an overview of clinical evidence reported in the literature. Today, more evidence has been provided for CT imaging, however, PET imaging offers the promise of direct imaging of biological processes and functions. We provide a summary of future research directions, which needs to be addressed in order to successfully introduce radiomics into clinical medicine. In comparison to CT, more focus should be directed towards harmonization of PET acquisition and reconstruction protocols, which is important for transferable modelling. Conclusions: Both CT and PET radiomics are promising pre-treatment and intra-treatment biomarkers for outcome prediction. Most studies are performed in retrospective setting, however their validation in prospective data collections is ongoing.

Present and future of clinical cardiovascular PET imaging in Europe—a position statement by the European Council of Nuclear Cardiology (ECNC)

Hybrid cardiac imaging using PET/MRI: a joint position statement by the European Society of Cardiovascular Radiology (ESCR) and the European Association of Nuclear Medicine (EANM)

Clinical Application of PET Myocardial Perfusion Imaging

Clinical use of quantitative cardiac perfusion PET: rationale, modalities and possible indications. Position paper of the Cardiovascular Committee of the European Association of Nuclear Medicine (EANM)

Positron emission tomography imaging in cardiovascular disease

Cardiac PET: metabolic and functional imaging of the myocardium

International Consensus on Clinical Use of Presynaptic Dopaminergic Positron Emission Tomography Imaging in Parkinsonism.

Positron Emission Tomography in Heart Failure: From Pathophysiology to Clinical Application

Nuclear cardiac imaging for the diagnosis and management of heart failure: what can be learned from recent guidelines?

Complementary Value of Cardiac FDG PET and CT for the Characterization of Atherosclerotic Disease

Myocardial Perfusion PET for the Detection and Reporting of Coronary Microvascular Dysfunction: A JACC: Cardiovascular Imaging Expert Panel Statement

Computed tomography and nuclear medicine for the assessment of coronary inflammation: clinical applications and perspectives

Role of Positron Emission Tomography Cardiac Perfusion Imaging in Clinical Management, Prognosis, and Risk Stratification of Cardiovascular Disease

Role of PET in the Evaluation and Understanding of Coronary Physiology

Cardiac CT for Myocardial Ischaemia Detection and Characterization—comparative Analysis

Current Applications of PET/MR: Part II: Clinical Applications II

PET/MR co-imaging in cardiovascular diseases: Current clinical applications and future development

From the basement to forefront of imaging: the future of nuclear medicine.

Nuclear medicine in the assessment and prevention of cancer therapy-related cardiotoxicity: prospects and proposal of use by the European Association of Nuclear Medicine (EANM)

CT radiomics and PET radiomics: ready for clinical implementation?

Cardiac PET for translational imaging